Bivalirudin or heparin treatment during transcatheter valve interventions: Where are we now?

Current Pharmaceutical Design

Volumn 22, Issue 13, 2016, Pages 1911-1917

  Mastoris, Ioannis ^a   Dangas, George D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bivalirudin; Procedural anticoagulation; Transcatheter aortic valve replacement

Indexed keywords

HEPARIN; HIRULOG; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; ANTITHROMBIN; BIVALIRUDIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; AORTIC VALVE REPAIR; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CEREBROVASCULAR ACCIDENT; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSLUMINAL VALVULOPLASTY; ADVERSE EFFECTS;

ANTICOAGULANTS; ANTITHROMBINS; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84964240598     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151208122005     Document Type: Article

References (65)

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. The Lancet 2006; 368(9540): 1005-11.
2. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve disease. Eur Heart J1987; 8(5): 471-83.
3. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363(17): 1597-607.
4. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364(23): 2187-98.
5. Genereux P, Head SJ, Wood DA, et al. Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications. Eur Heart J 2012; 33(19): 2388-98.
6. Rodes-Cabau J. Transcatheter aortic valve implantation: current and future approaches. Nat Rev Cardiol 2012; 9(1): 15-29.
7. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366(18): 1686-95.
8. Miller DC, Blackstone EH, Mack MJ, et al. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thoracic Cardiovasc Surg 2012; 143(4): 832-43.e13.
9. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aorticvalve replacement for inoperable severe aortic stenosis. N Engl J Med 2012; 366(18): 1696-704.
10. Genereux P, Webb JG, Svensson LG, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am College Cardiol 2012; 60(12): 1043-52.
11. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012; 60(15): 1438-54.
12. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials a consensus report from the valve academic research consortium. J Am Coll Cardiol 2011; 57(3): 253-69.
13. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aorticvalve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370(19): 1790-8.
14. Abdel-Wahab M, Mehilli J, Frerker C, et al. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: The choice randomized clinical trial. JAMA 2014; 311(15): 1503-14.
15. Omran H, Schmidt H, Hackenbroch M, Illien S, Bernhardt P, von der Recke G, et al. Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study. Lancet 2003; 361(9365): 1241-6.
16. Marechaux S, Corseaux D, Vincentelli A, et al. Identification of tissue factor in experimental aortic valve sclerosis. Cardiovasc Pathol 2009; 18(2): 67-76.
17. Abdel-Wahab M, Mehilli J, Frerker C, et al. Comparison of Balloon-Expandable vs Self-expandable Valves in Patients Undergoing Transcatheter Aortic Valve Replacement: The CHOICE Randomized Clinical Trial. JAMA 2014; 311(15): 1503-14.
18. Hynes BG, Rodes-Cabau J. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art. Ann New York Acad Sci 2012; 1254: 151-63.
19. Fairbairn TA, Mather AN, Bijsterveld P, et al. Diffusion-weighted MRI determined cerebral embolic infarction following transcatheter aortic valve implantation: assessment of predictive risk factors and the relationship to subsequent health status. Heart (British Cardiac Society) 2012; 98(1): 18-23.
20. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The french study of aortic plaques in stroke group. N Engl J Med1996; 334(19): 1216-21.
21. Holmes DR, Jr., Mack MJ, Kaul S, et al 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am College Cardiol 2012; 59(13): 1200-54.
22. Mastoris I, Schoos MM, Dangas GD, Mehran R. Stroke after transcatheter aortic valve replacement: incidence, risk factors, prognosis, and preventive strategies. Clin Cardiol 2014; 37(12): 756-64.
23. Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108(12): 1772-6.
24. Durand E, Blanchard D, Chassaing S, et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014; 113(2): 355-60.
25. Baber U, Mastoris I, Mehran R. Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat Rev Cardiol 2014; 11(12): 693-703.
26. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369(13): 1206-14.
27. Kadakia MB, Desai NR, Alexander KP, et al. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION registry–GWTG (national cardiovascular data registry acute coronary treatment and intervention outcomes network registry–get with the guidelines). JACC: Cardiovasc Interv 2010; 3(11): 1166-77.
28. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the american heart association. Circulation 2001; 103(24): 2994-3018.
29. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary interven tion: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126(3 Suppl): 576S-99S.
30. Doherty TM, Shavelle RM, French WJ. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2005; 65(3): 330-7.
31. Webb J, Rodes-Cabau J, Fremes S, Pibarot P, Ruel M, Ibrahim R, et al. Transcatheter aortic valve implantation: a Canadian cardiovascular society position statement. Can J Cardiol 2012; 28(5): 520-8.
32. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint task force on the management of valvular heart disease of the european society of cardiology (ESC) and the european association for cardio-thoracic surgery (EACTS). Eur J Cardiothorac Surg 2012; 42(4): S1-44.
33. Shimada YJ, Nakra NC, Fox JT, Kanei Y. Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention. Am J Cardiol 2010; 105(5): 629-32.
34. Ferguson JJ, Fathy Waly HM, Le D, Thomakos N, Wilson JM. The effect of body weight and body surface area correction on the distribution of the ACT response to bolus doses of heparin for PTCA. J Invasive Cardiol 1998; 10(6): 318-22.
35. Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009; 135(6): 1651-64.
36. Jang I-K, Hursting MJ. When heparins promote thrombosis: Review of heparin-induced thrombocytopenia. Circulation 2005; 111(20): 2671-83.
37. Nikolsky E, Dangas GD. Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia. Semin Thromb Hemost 2004; 30(3): 305-14.
38. Suzuki S, Koide M, Sakamoto S, et al. Early onset of immunological heparin-induced thrombocytopenia in acute myocardial infarction. Blood Coagul Fibrinol 1997; 8(1): 13-5.
39. Linkins L-A, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141(2_suppl): e495S-e530S.
40. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141(2_suppl): e24S-e43S.
41. Yost G, Steinhubl S. Monitoring and Reversal of Anticoagulation and Antiplatelets. In: Dangas G, Ed. Interventional Pharmacology. Philadephia: Elsevier 2013; pp. 643-63.
42. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW, 2nd. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry1990; 29(30): 7095-101.
43. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000; 12 (Suppl F): 33F-6.
44. Abdel-Wahab M, Richardt G. Safety of bivalirudin in patients with coronary artery disease. Expert Opin Drug Saf 2012; 11(1): 141-50.
45. Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 2004; 103(2): 613-6.
46. Lange P, Greif M, Bongiovanni D, et al. Bivalirudin versus heparin in patients undergoing transcatheter aortic valve implantation. Can J Cardiol 2015; 31(8): 998-1003.
47. Boekstegers P, Lange P, Pohl T, Dangas G, Mastoris I, Steinbeck G. Feasibility of procedural anticoagulation with bivalirudin in transcatheter aortic valve implantation: The BiTAVI pilot study. J Invasive Cardiol 2015; in press.
48. Kini A, Yu J, Cohen MG, et al. Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention 2014; 10(3): 312-9.
49. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve academic research consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg 2012; 42(5): S45-60.
50. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Acad Res Consortium J Am Coll Cardiol 2011; 57(3): 253-69.
51. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium. Circulation 2011; 123(23): 2736-47.
52. Scott B, Tam CW, Moon RS. Transfemoral transcatheter aortic valve replacement in a patient with heparin-induced thrombocytopenia: Intraoperative anticoagulation management with bivalirudin (Angiomax). J Cardiothorac Vasc Anesth 2015; 29(6): 1603-5.
53. Sangani NK, Greason KL, Torres NE, Suri RM, Mathew V. Bivalirudin and transcatheter aortic valve replacement: a cautionary tale. Ann Thorac Surg 2014; 98(6): 2214-5.
54. Sergie Z, Lefevre T, Van Belle E, et al. Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. J Thromb Thrombol 2013; 35(4): 483-93.
55. Erdoes G, Basciani R, Huber C, et al. Transcranial Dopplerdetected cerebral embolic load during transcatheter aortic valve implantation. Eur J Cardiothorac Surg 2012; 41(4): 778-83; discussion 83-4.
56. Kahlert P, Al-Rashid F, Dottger P, et al. Cerebral embolization during transcatheter aortic valve implantation: A transcranial doppler study. Circulation 2012; 126(10): 1245-55.
57. Meredith Am IT, Walters DL, Dumonteil N, et al. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol 2014; 64(13): 1339-48.
58. Schofer J, Colombo A, Klugmann S, et al. Prospective multicenter evaluation of the direct flow medical transcatheter aortic valve. J Am Coll Cardiol 2014; 63(8): 763-8.
59. Van Mieghem NM, Schipper ME, Ladich E, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation 2013; 127(22): 2194-201.
60. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet 1992; 340(8810): 35-7.
61. Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67(3): 758-61.
62. Veyradier A, Balian A, Wolf M, et al. Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology 2001; 120(2): 346-53.
63. Federici AB, Rand JH, Bucciarelli P, et al. Acquired von willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84(2): 345-9.
64. Loscalzo J. From Clinical observation to mechanism — Heyde's Syndrome. N Engl J Med 2012; 367(20): 1954-6.
65. Généreux P, Cohen DJ, Williams MR, et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacementinsights from the PARTNER I trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol 2014; 63(11): 1100-9.